

# Dr. Ross A. Dunne

## Curriculum Vitae (short version)

January 9, 2026

brainHealth Manchester  
70 Daisybank Road  
Manchester M14 5QN  
✉ ross.dunne@gmmh.nhs.uk  
>ID 0000-0003-2046-6193  
👤 sadneurons  
👤 ross-dunne-gmdrc  
GMC: 7250794  
Specialist Register: 19/8/15



### Summary

Consultant in Old Age Psychiatry and Clinical Director of Greater Manchester Dementia Research Centre. Established UK's first psychiatrist-led CSF biomarker service (2022), scaled into Manchester Brain Health Centre with £35M industry investment. PI/Co-I on 30+ Phase I-III trials; research portfolio exceeding £15M. Focus: platform trials for disease-modifying therapies, molecular diagnostics, vascular cognitive impairment.

### Education & Qualifications

- 2010 **PgDipStat**, Trinity College Dublin
- 2010 **MRCPsych**, Royal College of Psychiatrists
- 2005 **MB BCh BAO**, Trinity College Dublin

### Current Appointments

- 2024– **NIHR-RDN NW England Dementia Clinical Lead**
- 2021– **Board Member/Dementia Theme Co-Lead**, Geoffrey Jefferson BRC
- 2020– **Theme Lead for Dementia**, Health Innovation Manchester
- 2019– **Clinical Director**, Greater Manchester Dementia Research Centre
- 2015– **Consultant in Old Age Psychiatry**, GMMH Foundation Trust

### Selected Leadership Roles

- 2019– **Clinical Director**, Greater Manchester Dementia Research Centre  
Leading NW's largest dementia research centre (7 staff, 9 ongoing studies). Managing commercial/grant portfolio across Phase I-III trials. Member of national Dementia Trials Network.
- 2022– **Founder/Clinical Lead**, Manchester Brain Health Centre  
Established UK's first psychiatrist-led CSF biomarker clinic. Scaled into comprehensive Brain Health Centre with molecular diagnostics, cardiovascular profiling, and risk reduction interventions. £35M industry investment.

### Key Grants (Recent; £14M+ total)

- 2026–31 **Treating auditory impairment in MCI**, NIHR PGfAR, £3.4M, Co-App
- 2025–30 **AD-SMART Platform Trial**, MRC/DRI/ARUK, £7.5M, Co-I
- 2025–27 **Manchester Brain Health Centre**, AlzSoc, £1.5M, Clinical Director
- 2024–29 **READ-OUT Real world outcomes**, ARUK/AlzSoc/NIHR, £4.5M, Site PI
- 2023–28 **ANTLER75+ Depression withdrawal**, NIHR HTA, £1.95M, Site PI
- 2023–26 **All-in-One MCI imaging**, Alzheimer's Society, £384K, PI

### Awards & Honors

- 2025 **HSJ Award**, Best NHS Collaboration & Best Pharmaceutical Partnership
- 2024 **ACCIA National Clinical Impact Award Level N1**
- 2023 **HSJ Award**, Modernising Diagnostics (brainHealth Manchester)

### Clinical Trials Experience

- Overview PI/Co-I on 30+ trials across AD monoclonal antibodies (Aducanumab, Gantenerumab, AL002), AD therapeutics (semaglutide, tau ASO), neuropsychiatric symptoms, and biomarker/platform studies (AD-SMART, READOUT, AllinOne). Extensive Phase I-III experience.
- Current Gabriella (Roche), CELIA (Biogen), AD-SMART (MRC), ANTLER75+ (NIHR), CICERO (NIHR), AllinOne (Alz-Soc), READOUT (ARUK/NIHR), ABHAD (BRC)

### Innovation & Service Development

- Brain Health** Established UK's first psychiatrist-led CSF biomarker clinic (2022). Personally developed lab protocols, scaled into Manchester Brain Health Centre with comprehensive molecular diagnostics, cardiovascular profiling, and risk reduction using Motivational Interviewing. Advised 10+ UK/international sites on replication.
- Regional MDT** Convened regional MDT (2024) with neurology, neuroradiology, nuclear medicine for safe implementation of monoclonal antibody therapies in AD.

## Selected Publications (h-index: 20+)

- [1] Dunne, R. Coulthard, E. "Tipping the scales towards routine APOE genotyping". In: *Journal of Neurology, Neurosurgery & Psychiatry* 94.9 (2023). Editorial, pp. 669–669. DOI: [10.1136/jnnp-2023-332045](https://doi.org/10.1136/jnnp-2023-332045).
- [2] Taylor, J. L. "Uncoupling of Ca<sub>2+</sub> sparks from BK channels in cerebral arteries underlies hypoperfusion in hypertension-induced vascular dementia". In: *Proceedings of the National Academy of Sciences* 120.33 (2023), e2307513120. DOI: [10.1073/pnas.2307513120](https://doi.org/10.1073/pnas.2307513120).
- [3] Dunne, R. A. "Mild cognitive impairment: the Manchester consensus". In: *Age and ageing* 50.1 (2021), pp. 72–80. DOI: [10.1093/ageing/afaa228](https://doi.org/10.1093/ageing/afaa228).
- [4] Semkovska, M. "Bitemporal versus high-dose unilateral twice-weekly electroconvulsive therapy for depression (EFFECT-Dep): a pragmatic, randomized, non-inferiority trial". In: *American Journal of Psychiatry* 173.4 (2016), pp. 408–417. DOI: [10.1176/appi.ajp.2015.15030372](https://doi.org/10.1176/appi.ajp.2015.15030372).
- [5] Dunne, R. A. McLoughlin, D. M. "Systematic review and meta-analysis of bifrontal electroconvulsive therapy versus bilateral and unilateral electroconvulsive therapy in depression". In: *The World Journal of Biological Psychiatry* 13.4 (2012), pp. 248–258. DOI: [10.3109/15622975.2011.608473](https://doi.org/10.3109/15622975.2011.608473).

Full publication list (30+ peer-reviewed articles): available on request or ORCID 0000-0003-2046-6193

## Research Skills

- |               |   |
|---------------|---|
| Clinical      | Trial design/coordination, GCP, ethics, lumbar puncture, CSF biomarker processing. Rating scales: RBANS, CDR, ADAS-Cog, MADRS, MMSE, MoCA, PWV, audiometry.                                     |
| Technical     | R, Python, C++, mixed-effects modelling (lmer), TensorFlow/PyTorch, LaTeX, Linux/BASH, web development (Django, JavaScript). PgDipStat (TCD), ONS Safe Researcher, Google Python certification. |
| Current Study | BSc Mathematics (Open University, in progress)  |

## Teaching & Training

Undergraduate tutor (TCD, Cambridge, Manchester). Faculty member, Neurology Academy Sheffield. Registered trainer/educational supervisor for higher trainees in old age psychiatry.

## Service & Leadership

- |                           |   |
|---------------------------|---|
| UK Brain Health Coalition | Founder member and Co-Chair (ARUK/AlzSoc). Lead national dissemination of early diagnosis approaches.     |
| Grant Review              | Co-chair, Alzheimer's Society UK (2022–25); Board member ARUK (2023–25), Alzheimer Society Ireland (2023) |
| Trial Oversight           | TSC member and chair COBALT (NIHR EME). Peer reviewer for journals and NIHR i4i programme.                |
| Editorial                 | Guest editor, British Journal of Psychiatry special issue on DMTs in AD (2023)                            |

## Key Collaborations

- University of Manchester Prof Stuart Allan (Neuroscience, MaVRICS), Prof Adam Greenstein (CV Sciences), Prof Laura Parkes (Neuroimaging, AllinOne), Dr Sasha Philbert (CV Sciences, Na-MRI), Dr Karen Hampson (Vision Science, retinal biomarkers), Dr Jenna Littlejohn (Hearing BRC, ABHAD)

## Professional Memberships

- Royal College of Psychiatrists (2010–)
- British Geriatric Society (2017–)
- International Psychogeriatric Association (2019–)
- International Parkinson's and Movement Disorders Society (2018–)

## References

Available upon request